These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 9102222

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
    Gambotto A, Tüting T, McVey DL, Kovesdi I, Tahara H, Lotze MT, Robbins PD.
    Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Development of HPV16 positive cervical cancer model in the hu-PBL-SCID mouse and its immunological features].
    Liang ZX, Cheng Q, Chen HZ, Xie X, Ye DF.
    Zhonghua Yi Xue Za Zhi; 2004 Sep 02; 84(17):1465-9. PubMed ID: 15500747
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Targeting p53 for adoptive T-cell immunotherapy.
    McCarty TM, Liu X, Sun JY, Peralta EA, Diamond DJ, Ellenhorn JD.
    Cancer Res; 1998 Jun 15; 58(12):2601-5. PubMed ID: 9635585
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ, Ribas A, Butterfield LH, Vollmer CM, Eilber FC, Dissette VB, Nelson SD, Shintaku P, Mekhoubad S, Nakayama T, Taniguchi M, Glaspy JA, McBride WH, Economou JS.
    Cancer Res; 2000 Nov 15; 60(22):6457-64. PubMed ID: 11103813
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor.
    Kanagawa N, Gao JQ, Motomura Y, Yanagawa T, Mukai Y, Yoshioka Y, Okada N, Nakagawa S.
    Biochem Biophys Res Commun; 2008 Aug 08; 372(4):821-5. PubMed ID: 18519033
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M, Nishigori C, Ichihashi M.
    Exp Dermatol; 2004 Oct 08; 13(10):613-20. PubMed ID: 15447721
    [Abstract] [Full Text] [Related]

  • 40. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
    Wang L, Qi X, Sun Y, Liang L, Ju D.
    Cancer Gene Ther; 2002 Oct 08; 9(10):819-24. PubMed ID: 12224022
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.